Head-to-head
BPC-157 vs Ipamorelin
A field-by-field comparison of BPC-157 and Ipamorelin drawn from the PeptideIndex database: mechanism, evidence grade, half-life, administration route, reported dosing, side effects, storage and legal status. They belong to different categories — recovery & repair and growth hormone — so this page focuses on what each one actually does rather than which is "better".
BPC-157 vs Ipamorelin: editorial summary
BPC-157 and ipamorelin represent two very different areas of peptide research. BPC-157 is associated primarily with tissue-repair and gastrointestinal research, whereas ipamorelin is a selective growth-hormone secretagogue.
Key considerations
- BPC-157's proposed mechanisms include effects on angiogenesis, nitric-oxide signalling and tendon fibroblasts. Ipamorelin instead activates GHS-R1a to stimulate GH release. Consequently, the two compounds should not be treated as alternatives simply because both appear in broader recovery or body-composition discussions.
- Evidence maturity is also different: BPC-157 is rated Emerging and is predominantly supported by preclinical work, while ipamorelin is rated Moderate.
BPC-157 characteristics
- BPC-157 is a 15-amino-acid recovery-and-repair peptide with predominantly preclinical evidence.
Ipamorelin characteristics
- Ipamorelin is a selective pentapeptide GH secretagogue. PeptideIndex describes its evidence as Moderate and emphasises its relative selectivity compared with older GH secretagogues.
BPC-157 vs Ipamorelin at a glance
| Attribute | BPC-157 | Ipamorelin |
|---|---|---|
| Category | Recovery & repair | Growth hormone |
| Evidence grade | Emerging | Moderate |
| Also known as | Body Protection Compound 157, PL 14736 | NNC 26-0161 |
| Chain | 15 amino acids (GEPPPGKPADDAGLV) | Pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) |
| Mechanism | Appears to upregulate growth-hormone receptor expression in tendon fibroblasts and promote angiogenesis via the VEGFR2–Akt–eNOS pathway, accelerating the formation of new blood vessels at an injury site. It also modulates nitric oxide signalling and appears protective of the gut lining. | Acts as a ghrelin receptor (GHS-R1a) agonist on the pituitary, triggering a clean GH pulse. Its selectivity avoids the appetite and cortisol effects seen with older secretagogues like GHRP-6. |
| Reported benefits | Faster tendon, ligament and muscle healing in rodent models · Protective effect on the gastrointestinal lining, including NSAID-induced damage · Reduced local inflammation around injury sites · Anecdotal relief from tendinopathy and joint pain | Clean GH pulse without hunger spikes · Better sleep quality and recovery · Mild fat-loss and body-composition support |
| Reported side effects | Injection-site irritation · Transient dizziness or nausea · Unknown long-term safety profile | Mild headache · Injection-site redness · Light-headedness shortly after dosing |
| Half-life | Approximately 4 hours (stable oral form debated) | About 2 hours |
| Administration | Subcutaneous injection; oral capsules used for gut-specific goals | Subcutaneous injection, 1–3 times daily |
| Dosing overview | Commonly cited in literature at 200–500 mcg once or twice daily for 4–8 weeks | 200–300 mcg per dose, often 100–300 mcg before bed |
| Storage | Lyophilised powder refrigerated; reconstituted vials 2–8 °C, used within ~30 days | Reconstituted vials refrigerated 2–8 °C, stable ~4 weeks |
| Legal status | Not FDA-approved. Research-chemical status in most countries; prohibited in sport. | Not FDA-approved; compounding restrictions apply in the US. Banned in sport. |
Key differences between BPC-157 and Ipamorelin
Different categories, different goals
BPC-157 is indexed under recovery & repair, while Ipamorelin sits under growth hormone. They are not substitutes for one another: BPC-157 is described as "A synthetic fragment of a protein found in gastric juice, widely used in the recovery community for tendon, gut and soft-tissue complaints." and Ipamorelin as "The most selective of the growth-hormone secretagogues, valued because it lifts GH without meaningfully raising cortisol or prolactin."
Mechanism of action
BPC-157: Appears to upregulate growth-hormone receptor expression in tendon fibroblasts and promote angiogenesis via the VEGFR2–Akt–eNOS pathway, accelerating the formation of new blood vessels at an injury site. It also modulates nitric oxide signalling and appears protective of the gut lining. Ipamorelin: Acts as a ghrelin receptor (GHS-R1a) agonist on the pituitary, triggering a clean GH pulse. Its selectivity avoids the appetite and cortisol effects seen with older secretagogues like GHRP-6.
Evidence quality is not equal
BPC-157 carries a Emerging evidence grade and Ipamorelin a Moderate grade on this index. The grade describes the quality of published human data, not how well a compound works — Ipamorelin has the better-documented record of the two, and claims made about BPC-157 rest on thinner human evidence.
Half-life and dosing frequency
BPC-157 is listed at approximately 4 hours (stable oral form debated); Ipamorelin at about 2 hours. That difference is what drives the reported schedules: Commonly cited in literature at 200–500 mcg once or twice daily for 4–8 weeks versus 200–300 mcg per dose, often 100–300 mcg before bed
Route of administration
BPC-157 is administered by subcutaneous injection; oral capsules used for gut-specific goals. Ipamorelin is administered by subcutaneous injection, 1–3 times daily.
Legal and regulatory status differs
BPC-157: Not FDA-approved. Research-chemical status in most countries; prohibited in sport. Ipamorelin: Not FDA-approved; compounding restrictions apply in the US. Banned in sport. This is usually the most practical difference between two compounds, because it determines whether a supply chain is labelled and regulated at all.
Handling and storage
BPC-157 is stored lyophilised powder refrigerated; reconstituted vials 2–8 °c, used within ~30 days. Ipamorelin is stored reconstituted vials refrigerated 2–8 °c, stable ~4 weeks.
What BPC-157 and Ipamorelin have in common
On the attributes tracked in this database — category, evidence grade, mechanism, half-life, administration, dosing overview, storage and legal status — BPC-157 and Ipamorelin share no identical values. They are compared here because they come up together in the same searches, not because they overlap.
Each compound in brief
BPC-157
Recovery & repair · Emerging evidence
A synthetic fragment of a protein found in gastric juice, widely used in the recovery community for tendon, gut and soft-tissue complaints.
Considerations: Nearly all evidence is preclinical (rodent); robust human trials are absent · Injected near the injury site is the common anecdotal practice, though systemic effects are proposed · Banned by WADA for competing athletes
Ipamorelin
Growth hormone · Moderate evidence
The most selective of the growth-hormone secretagogues, valued because it lifts GH without meaningfully raising cortisol or prolactin.
Considerations: Weakest GH release of the GHRPs — usually stacked with CJC-1295 · Effects build over weeks, not days · Dose ceiling: more than ~300 mcg per pulse gives diminishing returns
Frequently asked questions
What is the main difference between BPC-157 and ipamorelin?
BPC-157 is primarily studied in tissue-repair models, while ipamorelin stimulates growth-hormone release through the GHS-R1a receptor.
Do BPC-157 and ipamorelin have the same evidence level?
No. PeptideIndex rates BPC-157 Emerging and ipamorelin Moderate.
Are BPC-157 and ipamorelin direct alternatives?
Not based on their mechanisms. They target substantially different biological pathways.
Related comparisons and reading
Every figure on this page is reproduced from the compound profiles in this database and reflects published literature and commonly reported protocols. It is educational information, not medical advice, and not a recommendation to use either compound. See the medical disclaimer.